GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » PS Ratio

Ensol Biosciences (XKRX:140610) PS Ratio : 358.36 (As of Jun. 23, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ensol Biosciences's share price is ₩5900.00. Ensol Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₩16.46. Hence, Ensol Biosciences's PS Ratio for today is 358.36.

The historical rank and industry rank for Ensol Biosciences's PS Ratio or its related term are showing as below:

XKRX:140610' s PS Ratio Range Over the Past 10 Years
Min: 66.92   Med: 240.82   Max: 451.29
Current: 358.36

During the past 10 years, Ensol Biosciences's highest PS Ratio was 451.29. The lowest was 66.92. And the median was 240.82.

XKRX:140610's PS Ratio is ranked worse than
93.6% of 1000 companies
in the Biotechnology industry
Industry Median: 8.875 vs XKRX:140610: 358.36

Ensol Biosciences's Revenue per Sharefor the six months ended in Dec. 2023 was ₩16.46. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₩16.46.

Warning Sign:

Ensol Biosciences Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Ensol Biosciences was -81.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -37.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -11.20% per year.

During the past 10 years, Ensol Biosciences's highest 3-Year average Revenue per Share Growth Rate was 34.30% per year. The lowest was -37.60% per year. And the median was 1.80% per year.

Back to Basics: PS Ratio


Ensol Biosciences PS Ratio Historical Data

The historical data trend for Ensol Biosciences's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences PS Ratio Chart

Ensol Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 156.01 214.50 394.75 90.64 377.79

Ensol Biosciences Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only 156.01 214.50 394.75 90.64 377.79

Competitive Comparison of Ensol Biosciences's PS Ratio

For the Biotechnology subindustry, Ensol Biosciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ensol Biosciences's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensol Biosciences's PS Ratio distribution charts can be found below:

* The bar in red indicates where Ensol Biosciences's PS Ratio falls into.



Ensol Biosciences PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Ensol Biosciences's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=5900.00/16.464
=358.36

Ensol Biosciences's Share Price of today is ₩5900.00.
For company reported annually, GuruFocus uses latest annual data as the TTM data. Ensol Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₩16.46.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Ensol Biosciences  (XKRX:140610) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Ensol Biosciences PS Ratio Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ensol Biosciences (XKRX:140610) Business Description

Traded in Other Exchanges
N/A
Address
51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036
Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences (XKRX:140610) Headlines

No Headlines